Design and endpoints of clinical trials in hepatocellular carcinoma

JM Llovet, AM Di Bisceglie, J Bruix… - Journal of the …, 2008 - academic.oup.com
The design of clinical trials in hepatocellular carcinoma (HCC) is complex because many
patients have concurrent liver disease, which can confound the assessment of clinical …

The treatment of chronic viral hepatitis

JH Hoofnagle, AM Di Bisceglie - New England Journal of …, 1997 - Mass Medical Soc
Chronic viral hepatitis is the principal cause of chronic liver disease, cirrhosis, and
hepatocellular carcinoma in the world and now ranks as the chief reason for liver …

[PDF][PDF] Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease

WR Kim, SL Flamm, AM Di Bisceglie… - …, 2008 - Wiley Online Library
This document presents the official position of the American Association for the Study of
Liver Diseases (AASLD) on the application of serum alanine aminotransferase (ALT) activity …

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

EM Brunt, CG Janney, AM Di Bisceglie… - Official journal of the …, 1999 - journals.lww.com
OJECTIVE: Steatohepatitis is a morphological pattern of liver injury that may be seen in
alcoholic or nonalcoholic liver disease. This pattern may occur with obesity, diabetes, the …

[HTML][HTML] Telaprevir for previously untreated chronic hepatitis C virus infection

IM Jacobson, JG McHutchison… - … England Journal of …, 2011 - Mass Medical Soc
Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease
inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon …

[HTML][HTML] Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

N Afdhal, KR Reddy, DR Nelson, E Lawitz… - … England Journal of …, 2014 - Mass Medical Soc
Background Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients
who have not had a sustained virologic response to prior interferon-based therapy …

[HTML][HTML] Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

KV Kowdley, SC Gordon, KR Reddy… - … England Journal of …, 2014 - Mass Medical Soc
Background High rates of sustained virologic response were observed among patients with
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …

[HTML][HTML] Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher's disease

NW Barton, RO Brady, JM Dambrosia… - … England Journal of …, 1991 - Mass Medical Soc
Abstract Background and Methods. Gaucher's disease, the most prevalent of the
sphingolipid storage disorders, is caused by a deficiency of the enzyme glucocerebrosidase …

Recombinant interferon alfa therapy for chronic hepatitis C

AM Di Bisceglie, P Martin, C Kassianides… - … England Journal of …, 1989 - Mass Medical Soc
Infection with the hepatitis C virus may result in chronic liver disease for which no effective
therapy is now available. We studied the effects of recombinant human interferon alfa in a …

Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon

JH Hoofnagle, KD Mullen, DB Jones… - … England Journal of …, 1986 - Mass Medical Soc
We treated 10 patients who had chronic non-A, non-B hepatitis with recombinant human
alpha interferon in varying doses (0.5 to 5 million units) daily, every other day, or three times …